Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: HSBC announces redemption of US dollar securities

Thu, 15th Apr 2021 19:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.

----------

RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.

----------

Blue Star Capital PLC - investment company with a focus on esports, payments, technology and its applications within media and gaming - Says investee Dynasty eSports Pte Ltd achieved its first monthly profit on an operating basis in January. Says Dynasty expects to shortly conclude a round of fundraising in which it is targeting to raise approximately USD5 million. Blue Star retains anti-dilution rights and is considering exercising these rights to participate in Dynasty's fundraising round. Blue Star currently holds approximately 13% of Dynasty.

----------

Alliance Pharma PLC - pharmaceutical company based in Wiltshire - Says Non-Executive Director Nigel Clifford to step down on April 30 after serving for six years.

----------

Futura Medical PLC - Surrey-based pharmaceutical company - Receives conversion notice from HT Riverwood Multi-Growth Fund, managed by Atlantis Investment Management Ltd, for GBP1.5 million loan notes. Says following this there will be no further amounts outstanding to Riverwood. Says following the conversion, Futura will issue 7.5 million shares at a conversion price of 20 pence per share.

----------

CEPS PLC - Bath, England-based investment company focussed on the industrial sector - Says subsidiary Hickton Group Ltd enters a four-year GBP500,000 Coronavirus Business Interruption Loan with Santander UK PLC. Proceeds will be used for general corporate purposes. Says the loan is repayable in 11 consecutive equal quarterly payments starting approximately 12 months after drawdown.

----------

Tavistock Investments PLC - Berkshire-based investment manager - Says holders of 42% of its shares are against possible Team PLC offer. On Wednesday, Tavistock received letters of intent from holders of 25% of shares saying they will reject the possible all-share offer by Team. In addition, Tavistock board members, who own a 16% stake, would not accept an offer at that level from Team as it significantly undervalues the business. On March 23, Jersey-based investment manager Team announced a possible all-share offer for Tavistock worth GBP15.2 million, or 2.5 pence per share. Tavistock's market capitalisation is GBP15.8 million.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Withdraws application for maintenance of Europe Efmody orphan designation. Says this follows feedback from the Committee for Orphan Medicinal Products, an advisory committee to the European Medicines Agency. "Diurnal has decided that continuing pursuit of an Orphan Designation for the drug would be likely to cause a significant delay in its European commercial launch. First commercial launch is currently anticipated to be in Q3 2021," says Diurnal.

----------

Emmerson PLC - Khemisset potash project in northern Morocco - Completes phased development plan for Khemisset potash project. Expects "significantly reduced up-front capex" of USD254.6 million. Expects earnings before interest, tax, depreciation and amortisation in first full year of phase four production of USD491.4 million.

----------

CATCo Reinsurance Opportunities Fund Ltd - investor focused on offering returns from investments linked to catastrophe reinsurance risks - Advised of further side pocket investment release amounting to USD19.2 million. Says it is expected to be paid to the company in May, following which the company intends to use it to carry out a seventh compulsory redemption of its shares.

----------

Caerus Mineral Resources PLC - exploration & resource development company focused on minerals in Europe to supply global clean energy drive - Says drilling in Cyprus has begun ahead of schedule. Says Mines Department of Cyprus has accepted its applications for the Kapedes and Vrechia extension licences. Says formal granting of licences expected to take several months but will commence reconnaissance geological mapping and sampling in the interim.

----------

Valeura Energy Inc - Canada-based company engaged in the exploration, development and production of petroleum and natural gas in Turkey - Agrees with TBNG Ltd to amend long stop date for completion of the sale of its shallow conventional gas business for USD15.5 million. Valeura will be entitled to royalty payments over a five-year period, with a minimum royalty payment of USD1.0 million, and maximum of USD2.5 million.

----------

Chesterfield Resources PLC - copper explorer focused on Cyprus - Announces that it has commenced its 2021 mineral exploration campaign in Cyprus. The company is exploring for further copper, gold, zinc and silver, after its successful diamond drill programme of late 2020. Says 15 percussion drill holes are planned during April and May.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.